Crohn's Disease, Ulcerative Colitis, and Cosmetic Surgery: Why Remission Comes First, Timing Around Biologics and Steroids, Tummy Tucks Over Old Resection Scars, Perianal Disease and the BBL, and Pyoderma Gangrenosum

The patient is 36, has had Crohn's disease since college, and has spent the last two years in the longest remission of their adult life. A biologic infusion every eight weeks finally did what years of prednisone could not. Along the way they lost and regained forty pounds twice, acquired a midline scar and a right-sided scar from a bowel resection, and ended up with loose lower abdominal skin that no amount of exercise has touched. When they started researching Crohn's disease and cosmetic surgery, the consultations split neatly in two. One surgeon declined on the spot because of the word "Crohn's." Another booked a tummy tuck with liposuction for the following month without asking when the next infusion was due, whether the patient was still on any steroids, or what the gastroenterologist thought.

Both responses miss the point. Inflammatory bowel disease, the umbrella term for Crohn's disease and ulcerative colitis, is not usually a reason to refuse elective surgery, and people who have lived through years of flares, hospital stays, and steroid weight gain have as much reason as anyone to want their bodies back. But the disease touches nearly every part of a cosmetic plan: the timing, the medication calendar, the surgical approach to an abdomen that has already been opened, the nutrition and blood counts going in, the drugs used for pain and infection, and the way an unusual wound problem should be read. What follows takes those in order.

Crohn's disease and cosmetic surgery: why remission comes first

The short answer: elective cosmetic surgery should be scheduled during a sustained, objectively confirmed remission, not during or shortly after a flare, and the gastroenterologist who manages the disease should agree with the timing before anything is booked.

The Centers for Disease Control and Prevention has estimated that about three million American adults have been diagnosed with inflammatory bowel disease. Crohn's disease can involve any part of the digestive tract from mouth to anus, often in patches, and can burrow through the bowel wall to form fistulas and abscesses. Ulcerative colitis is confined to the lining of the colon and rectum and behaves more uniformly, though it can be just as disabling during a flare. Both are driven by an overactive immune response, both wax and wane, and both are now commonly treated with drugs that dampen the immune system, which is where most of the surgical questions begin.

Active inflammation is the first problem. A patient in a flare is often losing protein and blood, eating poorly, dehydrated, anemic, and taking steroids, all of which slow healing and raise the risk of infection. Inflammation itself makes blood more likely to clot. And a flare is not a stable baseline: weight, energy, and medication doses are all moving targets, which is exactly the situation in which elective surgery should wait. The broader case for operating only on a stable patient, made in the piece on cosmetic surgery with autoimmune disease, applies here with unusual force because the bowel is so central to nutrition.

"Remission" also needs a definition. Feeling well is a good sign, but symptoms and inflammation do not always match in Crohn's disease, and some patients feel fine with active disease on a scan or scope. Gastroenterologists increasingly rely on objective markers: a blood test for C-reactive protein, a stool test for calprotectin, and sometimes a recent colonoscopy or imaging study. A reasonable question to put to the gastroenterologist is simple: "Is my disease quiet enough, by your measures, that you would be comfortable with an elective operation in the next few months, and is there any change to my treatment coming that should happen first?" Many patients and their doctors look for several months of stable remission on a stable regimen before elective surgery. The answer, and any lab values behind it, belongs in the surgeon's chart along with the rest of the preoperative testing.

Weight is the second reason to wait. Inflammatory bowel disease produces weight swings in both directions: loss during flares, gain during steroid courses and recovery. Body contouring results depend on a stable weight, and a tummy tuck or liposuction performed at the low point after a flare, or the high point of a prednisone course, will not hold its shape once the body settles. The same weight-stability rule discussed in the piece on body contouring after bariatric surgery applies, for related reasons.

Biologics, steroids, and the medication calendar

The short answer: most maintenance drugs for inflammatory bowel disease are continued or only briefly paused around surgery, biologic infusions and injections are usually timed so the operation falls late in the dosing cycle, and steroids are the medication that matters most because they raise infection and wound risk and cannot be stopped abruptly.

Steroids come first because the evidence against them is the most consistent. In bowel surgery for inflammatory bowel disease, patients taking moderate to high doses of prednisone in the weeks before surgery have higher rates of infections and wound problems, a finding repeated across many studies. A threshold often cited is around 20 milligrams of prednisone a day for more than about six weeks, though risk climbs with dose and duration rather than switching on at a single number. For elective cosmetic surgery, the sensible position is that a patient who still needs regular steroids to control their disease is not yet in the remission described above. Patients who have recently finished a steroid course should also know that their adrenal glands may take time to recover, and that their surgeon and anesthesiologist need to know about any steroid use in the past year so they can judge whether extra steroid coverage during surgery is needed. Steroids should never be stopped suddenly to clear a surgical date; that can provoke a dangerous adrenal crisis and a flare. Patients wondering about the short steroid courses some surgeons use for swelling will find that question covered in the piece on steroids for swelling after plastic surgery.

Biologics are more nuanced. Anti-TNF drugs such as infliximab and adalimumab, along with vedolizumab, ustekinumab, risankizumab, and others, are the backbone of modern treatment. Older retrospective studies raised concern that recent anti-TNF exposure increased postoperative infections, but a large prospective U.S. study known as PUCCINI, which followed patients undergoing bowel surgery, did not find that recent anti-TNF use independently raised the risk of infection. That reassurance matters, because stopping a biologic for too long can trigger a flare and, with some drugs, the formation of antibodies that make the drug less effective when restarted. A common compromise, borrowed from the 2022 perioperative guideline published by the American College of Rheumatology and the American Association of Hip and Knee Surgeons for joint replacement, is to schedule the operation near the end of the dosing interval, when drug levels are lowest, and resume once the wounds are healing well and there is no sign of infection. For a patient on infusions every eight weeks, that often means operating in the week before the next infusion is due, then giving that dose a week or two late. The exact timing is a joint decision between the surgeon and the gastroenterologist.

The other drugs fall into simpler categories. Mesalamine and related drugs are generally continued or held only on the day of surgery. Azathioprine, mercaptopurine, and methotrexate are commonly continued through minor and moderate procedures, though some teams pause them briefly around larger operations. The newer oral small-molecule drugs, including the JAK inhibitors tofacitinib and upadacitinib and the S1P modulators ozanimod and etrasimod, have short half-lives; the rheumatology guideline mentioned above suggests holding JAK inhibitors for about three days before surgery, and similar logic guides the others. JAK inhibitors also carry an FDA boxed warning that includes blood clots, which feeds into the clot discussion below. Patients who are also using a GLP-1 drug for weight should add it to the list, given the anesthesia questions covered in the piece on GLP-1 drugs before plastic surgery.

"

The most dangerous medication decision in inflammatory bowel disease is not the one the surgeon makes. It is the one a patient makes alone, skipping an infusion or stopping prednisone to clear a surgical date, and then spending the recovery in a flare.

"

Tummy tucks and abdominal liposuction over a surgically altered abdomen

The short answer: a prior bowel resection does not rule out a tummy tuck or abdominal liposuction, but old scars change the blood supply to the skin, adhesions and hidden hernias change what a cannula can safely do, and active fistulas or abscesses must be resolved first.

Many people with Crohn's disease, and some with ulcerative colitis, have had abdominal surgery: a resection of the last part of the small intestine, a colectomy, a temporary or permanent stoma, or a removal of the colon with an internal pouch. Each leaves its mark. A long midline scar, a right-sided incision from an older open resection, multiple small laparoscopic scars, and the closed site of a former stoma all interrupt the blood vessels that feed the abdominal skin. The skin flap raised during a tummy tuck depends on the vessels that remain, and a scar in the wrong place can leave part of the flap undersupplied. The planning principles, including when a surgeon modifies the design, limits undermining, or avoids liposuction in certain zones, are laid out in the piece on old abdominal surgery scars and tummy tucks. A patient with an existing vertical midline scar is sometimes a candidate for a fleur-de-lis tummy tuck, which removes the old scar along with excess skin, though that pattern carries its own healing trade-offs.

Hernias are the hidden risk. Incisional hernias, in which bowel or fat bulges through a weakened area of the abdominal wall, are common after open bowel surgery and after stoma reversal, and they are not always visible or obvious on examination. A liposuction cannula passed through a hernia can injure the bowel, which is among the most serious complications in body contouring. Patients with prior abdominal surgery should expect a careful examination and often an imaging study, such as a CT scan or ultrasound, before abdominal liposuction or a tummy tuck. If a hernia is found, it may be repaired at the same time with a general surgeon, as described in the piece on umbilical hernia repair with a tummy tuck, or staged.

Some situations argue for waiting or for a general surgeon's involvement. An active fistula that drains to the skin, a recent intra-abdominal abscess, or a narrowed segment of bowel that may need surgery soon are all reasons to postpone cosmetic abdominal work; there is little sense in tightening an abdominal wall that a colorectal surgeon may need to open in a few months. Patients living with a stoma face their own set of questions, including garment fit, the location of the stoma relative to the tummy tuck incision, and the risk of parastomal hernias, all covered in the piece on ostomy and cosmetic surgery. Patients with an internal pouch, often called a J-pouch, after removal of the colon for ulcerative colitis tend to have more frequent, looser bowel movements and can become dehydrated more quickly, which matters during fasting before surgery and in the first days of recovery when nausea limits drinking.

Muscle plication, the tightening of separated abdominal muscles during a tummy tuck, is not ruled out by prior bowel surgery, but it increases pressure inside the abdomen. In a patient with extensive adhesions or recent surgery, some surgeons choose a more limited repair. The reasons a patient might need plication at all, and the alternatives, are covered in the piece on diastasis recti repair versus exercise.

Nutrition, iron, clots, and the drugs that cause flares

The short answer: iron deficiency, low protein, and vitamin deficiencies are common in inflammatory bowel disease and should be corrected before surgery, the clot risk is higher than a healthy patient's, and anti-inflammatory painkillers, some antibiotics, and heavy opioid use can each provoke trouble after an operation.

Anemia is common in inflammatory bowel disease, most often from iron deficiency caused by blood loss and poor absorption, sometimes compounded by low vitamin B12 in patients whose last section of small intestine is inflamed or has been removed. Oral iron is often poorly tolerated and poorly absorbed when the bowel is inflamed, so many patients need intravenous iron, which takes several weeks to raise hemoglobin. That timeline should be built into the surgical calendar rather than discovered at the pre-op visit. The reasons a low starting hemoglobin narrows the margin in body contouring are explained in the piece on anemia and blood loss before and after cosmetic surgery. Low protein stores, measured imperfectly by serum albumin, are associated with poor healing across surgery, and deficiencies in vitamin D, zinc, and folate are common enough that a targeted panel is reasonable. The general approach is covered in the piece on pre-op nutrition optimization.

Blood clots are the next concern. Inflammatory bowel disease roughly doubles to triples the risk of venous blood clots compared with the general population, and the risk is higher during flares and after surgery. A tummy tuck, especially combined with liposuction, is already among the higher-risk cosmetic operations for clots. For a patient with inflammatory bowel disease, formal risk scoring, leg compression devices during surgery, early walking, and a low threshold for a short course of blood-thinning injections are reasonable, along with attention to estrogen-containing birth control and JAK inhibitors. The general framework is described in the piece on blood clots after plastic surgery. Some patients with inflammatory bowel disease worry that blood thinners will cause bleeding from the bowel; in practice, short-term preventive doses are routinely given to hospitalized patients with flares, and the decision can be made with the gastroenterologist.

Pain control needs its own plan. Nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen, and ketorolac are a staple of modern cosmetic recovery, but they have been linked to flares of inflammatory bowel disease, and many gastroenterologists advise patients to avoid them. The trade-offs, and the alternatives, are discussed in the piece on ibuprofen and NSAIDs after cosmetic surgery. That pushes more of the burden onto acetaminophen, long-acting local anesthetics, and nerve blocks, the tools of opioid-sparing recovery. Opioids are not forbidden, but heavy or prolonged use is associated with worse outcomes in inflammatory bowel disease, and drugs that slow the bowel should be used cautiously in anyone with active colitis. Opioid constipation is also more complicated in a patient with strictures or a history of obstruction, which is worth reviewing alongside the general advice in the piece on constipation after plastic surgery.

Antibiotics are the last item on this list. Patients with inflammatory bowel disease are more susceptible to Clostridioides difficile, a bowel infection that thrives after antibiotics and can look exactly like a flare. A single dose of antibiotic before surgery is standard and reasonable. Long postoperative courses "just in case," still common in some cosmetic practices, carry more risk for these patients than for most. New diarrhea after surgery should prompt a stool test rather than an assumption that the disease has returned. And because dehydration from diarrhea, vomiting, or a pouch can arrive quickly, patients should know the warning signs and have a plan for fluids, the same concern raised in the piece on nausea after cosmetic surgery.

Perianal disease, the BBL, steroid weight, and pyoderma gangrenosum

The short answer: active perianal Crohn's disease is a strong reason to postpone a Brazilian butt lift and other procedures near the buttocks and groin, steroid-related changes in the face and body should settle before they are treated, and a rare wound condition called pyoderma gangrenosum must be recognized because it looks like infection and gets worse with surgery.

Perianal Crohn's disease, with fistulas, abscesses, and skin tags around the anus, affects a substantial minority of patients with Crohn's disease. A Brazilian butt lift involves harvesting fat, often from the lower back and flanks, and injecting it into the buttocks, with the patient lying face down for hours and then avoiding direct sitting for weeks. Fat grafts are living tissue with no blood supply of their own for the first days, and they are vulnerable to infection. Operating close to an active fistula or a recently drained abscess invites contamination and invites a wound complication that is hard to distinguish from the underlying disease. The safety issues already involved in buttock fat grafting are covered in the piece on Brazilian butt lift safety protocols, and the perianal questions overlap with those in the pieces on hemorrhoids and cosmetic surgery and hidradenitis suppurativa, a condition that is itself more common in people with Crohn's disease. A quiet, healed perianal area, confirmed by the gastroenterologist or colorectal surgeon, is a reasonable prerequisite.

Steroid weight changes deserve patience. Long or repeated prednisone courses can round the face, enlarge fat deposits at the back of the neck and the abdomen, and leave purple stretch marks. Many of these changes ease over months once the steroids stop. Patients who rush to liposuction, buccal fat removal, or a neck procedure while still on steroids, or soon after, may be treating a shape that would have softened on its own, and some fat removal decisions are not easily reversed. Waiting six months or more after the last steroid course before judging what remains is a sensible rule of thumb. Stretch marks, unlike puffiness, usually persist, and the realistic options are covered in the piece on old stretch marks that won't fade.

Pyoderma gangrenosum is the complication every surgeon operating on these patients should know about. It is an uncommon inflammatory skin condition, seen in a small percentage of people with inflammatory bowel disease, in which a wound or even a small skin injury turns into an expanding, painful ulcer with a purple, undermined border. The key feature is called pathergy: injury makes it worse. After surgery, it can appear days to a couple of weeks later along an incision, and it has been reported after breast reductions, breast lifts, and tummy tucks. It looks like a wound infection, cultures are often negative, antibiotics do not help, and the natural surgical response, cutting away dead tissue, makes it spread. Treatment is with steroids or other immune-suppressing drugs, often under a dermatologist's direction. Patients with inflammatory bowel disease, and especially those who have had pyoderma gangrenosum before, should tell their surgeon directly, and any wound that worsens despite antibiotics should raise the question. The more familiar causes of incision breakdown, which still account for most problems, are described in the pieces on wound dehiscence after cosmetic surgery and skin necrosis after facelifts and tummy tucks.

Finally, the setting. A small procedure under local anesthesia, such as a mole removal or a scar revision, needs little beyond normal precautions in a patient in remission. A tummy tuck combined with liposuction in a patient with prior bowel surgery, anemia corrected only recently, and a biologic on hold is a larger undertaking that belongs in an accredited facility with a clear plan for transfer to a hospital and a surgeon with admitting privileges, the standards discussed in the pieces on outpatient facility accreditation and how many procedures to combine in one surgery.

The honest summary

Crohn's disease and ulcerative colitis do not close the door on cosmetic surgery. They change the order of operations. The first step is a sustained remission, confirmed with objective markers rather than symptoms alone, and agreed by the gastroenterologist. Weight should be stable, and steroid-related changes should be given months to settle before they are treated.

Medications need a written calendar. Steroids are the biggest risk and cannot be stopped abruptly. Biologics are usually timed so the operation falls near the end of the dosing cycle, then resumed once healing is under way. Other drugs are continued or held briefly according to a plan agreed between the surgeon and the gastroenterologist. Iron, protein, and vitamin deficiencies should be corrected with enough lead time to matter.

An abdomen that has already been opened needs an imaging-informed plan for hernias, scars, and adhesions. Active fistulas, abscesses, and perianal disease are reasons to wait. Pain control should lean away from anti-inflammatory drugs, antibiotics should be used sparingly, and clot prevention taken seriously. A wound that worsens despite antibiotics should prompt the question of pyoderma gangrenosum before anyone reaches for a scalpel.

The patient at the top of this piece eventually had the tummy tuck, three months after the consultation that had booked it within a month. The gastroenterologist confirmed remission with a normal calprotectin, the surgeon ordered a CT scan that found a small hernia near the old right-sided incision, and a general surgeon repaired it during the same operation. Surgery was scheduled in the week before the next infusion, which was given ten days late once the incision was sealed. Pain control used a nerve block, scheduled acetaminophen, and a small supply of opioids, with no ibuprofen. The flare they had feared did not come, and the infusion schedule went back to normal by the following cycle.